2. Academic Validation
  3. Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma

Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma

  • Nat Commun. 2019 Nov 7;10(1):5076. doi: 10.1038/s41467-019-12846-7.
Dan Su 1 2 3,  Dadong Zhang 4,  Jiaoyue Jin 5 6,  Lisha Ying 7 6 8,  Miao Han 4,  Kaiyan Chen 9,  Bin Li 4,  Junzhou Wu 7 6 8,  Zhenghua Xie 4,  Fanrong Zhang 10,  Yihui Lin 4,  Guoping Cheng 5,  Jing-Yu Li 4,  Minran Huang 7 6 8,  Jinchao Wang 4,  Kailai Wang 7,  Jianjun Zhang 11 12,  Fugen Li 4,  Lei Xiong 4,  Andrew Futreal 11 13,  Weimin Mao 14 15 16
Affiliations

Affiliations

  • 1 Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China. sudan@zjcc.org.cn.
  • 2 Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China. sudan@zjcc.org.cn.
  • 3 Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. sudan@zjcc.org.cn.
  • 4 Research and Development Institute of Precision Medicine, 3D Medicines Inc., Shanghai, China.
  • 5 Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • 6 Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
  • 7 Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • 8 Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • 9 Department of Chemotherapy, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • 10 Department of Breast Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • 11 Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • 12 Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • 13 Honorary Faculty, Wellcome Trust Sanger Institute, Hinxton, UK.
  • 14 Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China. Weimin.mao@zjcc.org.cn.
  • 15 Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. Weimin.mao@zjcc.org.cn.
  • 16 Department of Thoracic Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China. Weimin.mao@zjcc.org.cn.
PMID: 31700061 DOI: 10.1038/s41467-019-12846-7
Abstract

Previous studies from the Cancer Cell Line Encyclopedia (CCLE) project have adopted commercial pan-cancer cell line models to identify drug sensitivity biomarkers. However, drug sensitivity biomarkers in esophageal squamous cell carcinoma (ESCC) have not been widely explored. Here, eight patient-derived cell lines (PDCs) are successfully established from 123 patients with ESCC. The mutation profiling of PDCs can partially recapture the tumor tissue actionable mutations from 161 patients with ESCC. Based on these mutations and relative pathways in eight PDCs, 46 targeted drugs are selected for screening. Interestingly, some drug and biomarker relationships are established that were not discovered in the CCLE project. For example, CDKN2A or CDKN2B loss is significantly associated with the sensitivity of CDK4/6 inhibitors. Furthermore, both PDC xenografts and patient-derived xenografts confirm CDKN2A/2B loss as a biomarker predictive of CDK4/6 inhibitor sensitivity. Collectively, patient-derived models could predict targeted drug sensitivity associated with actionable mutations in ESCC.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-50767
    99.94%, CDK4/6抑制剂
    CDK
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z